TARA - Protara Therapeutics Inc
Protara Therapeutics Inc Logo

TARA - Protara Therapeutics Inc

https://www.protaratx.com
Hold Momentum: Bearish
Recent News
Powered by Alpha Vantage
Neutral
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC - Protara Therapeutics ( NASDAQ:TARA )
Benzinga • 4 months, 2 weeks ago • score: 0.07
TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patients TARA-002 demonstrates 76% complete response rate at any time and 43% 12-month landmark complete response rate in BCG-Naïve patients
Neutral
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
GlobeNewswire • 4 months, 2 weeks ago • score: 0.09
NEW YORK, April 26, 2025 ( GLOBE NEWSWIRE ) -- Protara Therapeutics, Inc. ( Nasdaq: TARA ) , a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced updated results from its ongoing Phase 2 open-label ADVANCED-2 trial assessing ...
AI Tools
Key Metrics
Trend: Downtrend
As of 2025-09-10 (Snapshot)

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment of cancer and rare diseases. The company is headquartered in New York, New York.

52W High
$6.88
52W Low
$1.60
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.51
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
0.74
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
0.84
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
2.79%
Institutions (25–75% balanced)
78.74%
Shares Outstanding
38,581,900
Float
35,462,100
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-1.56
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.43%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
0.0083
Previous
0.0097
Trend
Falling
Signal Cross
No cross
As of
Sep. 05, 2025